NO20060678L - Triazolopyrimidinderivater som glykogensyntase-kinase 3-inhibitorer - Google Patents

Triazolopyrimidinderivater som glykogensyntase-kinase 3-inhibitorer

Info

Publication number
NO20060678L
NO20060678L NO20060678A NO20060678A NO20060678L NO 20060678 L NO20060678 L NO 20060678L NO 20060678 A NO20060678 A NO 20060678A NO 20060678 A NO20060678 A NO 20060678A NO 20060678 L NO20060678 L NO 20060678L
Authority
NO
Norway
Prior art keywords
optionally substituted
alkyl
alkyloxy
polyhaloci
polyhaloc
Prior art date
Application number
NO20060678A
Other languages
English (en)
Inventor
Ludwig Paul Cooymans
Eddy Jean Edgard Freyne
Werner Constant Joha Embrechts
Christopher John Love
Marc Willems
Nele Vandermaesen
Peter Jacobus Johan Buijnsters
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20060678L publication Critical patent/NO20060678L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Denne oppfinnelse vedrører en forbindelse med formel etN-oksid, et farmasøytisk akseptabelt addisjonssalt, et kvatemært amin og en stereokjemisk isomer form derav, hvori ring A representerer fenyl, pyridyl, pyrimidinyl, pyridazinyl eller pyrazinyl; R' representerer hydrogen; aryl; formyl; Ci.6alkylkarbonyl; Ci.6alkyl; Ci.6alkyloksykarbonyl; Ci.6alkyl substituert med formyl, Ci.6aUcyULarbonyl, Ci.6aUsyloksykarbonyl, Ci.6aUcylkarbonyloksy; eUer Ci-ealkyloksyCi-ealkylkarbonyl eventuelt substituert med Ci-ealkyloksykarbonyl; X representerer en direktebinding; -(CH2)n3- eller -(CH2)n4-Xia-Xib-; R^ representerer Cs-vcykloalkyl; fenyl; en 4, 5, 6- eller 7- leddet monocyklisk heterocykel inneholdende minst ett heteroatom valgt fra O, S eller N; benzoksazolyl eller et radikal med formel hvori R^ -substituenten eventuelt kan være substituert; R^ representerer halo; hydroksy; eventuelt substituert Ci.6aUcyl; C2.6aUcenyl eUer C2.6alkynyl, hver eventuelt substituert; eventuelt substituert polyhaloCi-eaUcyl; eventuelt substituert Ci-eaUcyloksy; eventuelt substituert polyhaloCi-ealkyloksy; Ci-ealkyltio; polyhaloCi-eaUcyltio; Ci-eaUcyl-oksykarbonyl; Ci-ealkyUcarbonyloksy; Ci-ealkyUcarbonyl; polyhaloCi-eaULyUcarbonyl; cyano; karboksyl; aiyloksy; aiyltio; aiyUcarbonyl; NR^R^^; C(=0)-NR^'^; -NR'-C(=0)-NR'^*; -NR'-C(=0)-R'; -S(=0)bi,-R^ -NR'-S(=0>,i- R**; -S-CN; -NR^-CN; R'^ representerer hydrogen; halo; hydroksy; eventuelt substituert Ci.4aUsyl; C2.4aUcenyl eller C2.4aUcynyl, hver eventuelt substituert; polyhaloCualkyl; eventuelt substituert Ci.4alkyloksy; polyhalo-CuaUsyloksy; Ci.4alkyltio; polyhaloCi.salkyltio; Ci.4alkyloksykarbonyl; Ci.4alkyULarbonyloksy; Ci.4alkyULarbonyl; polyhaloCi.4aUcyl-karbonyl; nitio; cyano; karboksyl; NR'°R"; C(=0)NR'°R"; -NR'-C(=0)-NR'°R"; -NR'-C(-0)-R'; -S(=0)ni-R''; -NR'-S(=0)ni-R''; -S-CN; -NR'-CN; deres anvendelse, farmasøytiske sammensetninger omfattende dem og fremgangsmåter for deres fremstiUing.
NO20060678A 2003-07-16 2006-02-10 Triazolopyrimidinderivater som glykogensyntase-kinase 3-inhibitorer NO20060678L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0350310 2003-07-16
PCT/EP2004/051455 WO2005012307A1 (en) 2003-07-16 2004-07-12 Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors

Publications (1)

Publication Number Publication Date
NO20060678L true NO20060678L (no) 2006-02-10

Family

ID=34112425

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060678A NO20060678L (no) 2003-07-16 2006-02-10 Triazolopyrimidinderivater som glykogensyntase-kinase 3-inhibitorer

Country Status (26)

Country Link
US (2) US7560458B2 (no)
EP (1) EP1658292B1 (no)
JP (1) JP2009514782A (no)
KR (1) KR20060120393A (no)
CN (1) CN100404536C (no)
AP (1) AP2006003486A0 (no)
AR (1) AR045698A1 (no)
AT (1) ATE370142T1 (no)
AU (1) AU2004260738B2 (no)
BR (1) BRPI0412596A (no)
CA (1) CA2531333A1 (no)
DE (1) DE602004008303T2 (no)
DK (1) DK1658292T3 (no)
EA (1) EA010109B1 (no)
ES (1) ES2290754T3 (no)
IL (1) IL173139A (no)
JO (1) JO2460B1 (no)
MX (1) MXPA06000540A (no)
NO (1) NO20060678L (no)
NZ (1) NZ545058A (no)
PA (1) PA8607001A1 (no)
PL (1) PL1658292T3 (no)
PT (1) PT1658292E (no)
TW (1) TW200524935A (no)
WO (1) WO2005012307A1 (no)
ZA (1) ZA200600385B (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CN103169708B (zh) 2002-07-29 2018-02-02 里格尔药品股份有限公司 用2,4‑嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
AU2004260738B2 (en) * 2003-07-16 2009-07-16 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
RS53109B (en) 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. 2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
DK1660458T3 (da) * 2003-08-15 2012-05-07 Irm Llc 2, 4-pyrimidindiaminer egnede i behandling af neoplastiske sygdomme, in-flammatoriske lidelser og lidelser i immunsystemet.
WO2005028434A2 (en) * 2003-09-18 2005-03-31 Conforma Therapeutics Corporation Novel heterocyclic compounds as hsp90-inhibitors
CA2580857A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
JP5094398B2 (ja) 2004-09-20 2012-12-12 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環式誘導体およびステアロイル−ＣｏＡデサチュラーゼのメディエータとしてのそれらの使用
WO2006034440A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
WO2006034341A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
TW200626138A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
WO2006034441A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
MX2007003318A (es) 2004-09-20 2007-05-18 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2577588C (en) 2004-10-29 2013-09-10 Tibotec Pharmaceuticals Ltd. Hiv inhibiting bicyclic pyrimidine derivatives
US7563781B2 (en) 2005-01-14 2009-07-21 Janssen Pharmaceutica Nv Triazolopyrimidine derivatives
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
NZ563454A (en) * 2005-06-08 2011-03-31 Rigel Pharmaceuticals Inc 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1991532B1 (en) 2006-02-24 2017-01-11 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100120717A1 (en) 2006-10-09 2010-05-13 Brown Jason W Kinase inhibitors
JP2010532381A (ja) * 2007-06-29 2010-10-07 サネシス ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用な複素環式化合物
CL2008001933A1 (es) * 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AU2011254550B2 (en) 2010-05-21 2013-11-07 Noviga Research Ab Novel pyrimidine derivatives
EP2688883B1 (en) 2011-03-24 2016-05-18 Noviga Research AB Pyrimidine derivatives
ES2655264T3 (es) 2012-01-28 2018-02-19 Merck Patent Gmbh Derivados de triazolo[4,5-d]pirimidina
AU2013230286B2 (en) 2012-03-07 2016-12-22 Merck Patent Gmbh Triazolopyrazine derivatives
ES2636936T3 (es) * 2013-03-05 2017-10-10 Merck Patent Gmbh Derivados de triazolo[4,5-d]pirimidina para el tratamiento de enfermedades tales como cáncer
ES2614872T3 (es) 2013-03-05 2017-06-02 Merck Patent Gmbh Derivados de 9-(aril o heteroaril)-2-(pirazolilo, pirrolidinilo o ciclopentilo) aminopurina como agentes anticancer
CA2911259A1 (en) 2013-05-06 2014-11-13 Merck Patent Gmbh Macrocycles as kinase inhibitors
US10414768B2 (en) * 2014-12-05 2019-09-17 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating cystic fibrosis
WO2017035528A1 (en) 2015-08-27 2017-03-02 Nantneuro, Llc Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
WO2017156527A1 (en) * 2016-03-11 2017-09-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase and janus kinase inhibitors for prevention of graft versus host disease
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5962594A (ja) * 1982-09-30 1984-04-10 Ss Pharmaceut Co Ltd ３，５―ジ置換―トリアゾロピリミジン誘導体
US20020040031A1 (en) * 2000-07-07 2002-04-04 Glasky Michelle S. Methods for prevention of accumulation of amyloid beta peptide in the central nervous system
US6737085B2 (en) * 2000-11-01 2004-05-18 Tokiwa Phytochemical Co., Ltd. Apocynum venetum extract for use as antidepressant
US7105532B2 (en) * 2000-12-19 2006-09-12 Smithkline Beecham Corporation Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors
AU2004260738B2 (en) * 2003-07-16 2009-07-16 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors

Also Published As

Publication number Publication date
ES2290754T3 (es) 2008-02-16
US7560458B2 (en) 2009-07-14
EA010109B1 (ru) 2008-06-30
EP1658292A1 (en) 2006-05-24
AU2004260738B2 (en) 2009-07-16
AR045698A1 (es) 2005-11-09
CN100404536C (zh) 2008-07-23
TW200524935A (en) 2005-08-01
AU2004260738A1 (en) 2005-02-10
ATE370142T1 (de) 2007-09-15
IL173139A0 (en) 2006-06-11
BRPI0412596A (pt) 2006-09-19
EA200600258A1 (ru) 2006-06-30
US20060205721A1 (en) 2006-09-14
PT1658292E (pt) 2007-10-25
DE602004008303T2 (de) 2008-05-08
US20090036471A1 (en) 2009-02-05
NZ545058A (en) 2008-05-30
WO2005012307A1 (en) 2005-02-10
ZA200600385B (en) 2007-05-30
CA2531333A1 (en) 2005-02-10
MXPA06000540A (es) 2006-03-30
EP1658292B1 (en) 2007-08-15
DE602004008303D1 (de) 2007-09-27
PA8607001A1 (es) 2005-05-10
CN1823068A (zh) 2006-08-23
AP2006003486A0 (en) 2006-02-28
KR20060120393A (ko) 2006-11-27
JP2009514782A (ja) 2009-04-09
PL1658292T3 (pl) 2008-01-31
IL173139A (en) 2010-04-29
JO2460B1 (en) 2009-01-20
DK1658292T3 (da) 2007-11-12

Similar Documents

Publication Publication Date Title
NO20060678L (no) Triazolopyrimidinderivater som glykogensyntase-kinase 3-inhibitorer
WO2005012304A3 (en) Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
DK1442019T3 (da) Amidderivater som glycogensynthasekinase 3- beta-inhibitorer
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
CO6241157A2 (es) "derivados de 6-(pirrolidin-3-il)-1h-pirazolo{3,4-d}pirimidin-4(5h)-ona utiles como inhibidores de pde9"
NO20041911L (no) Heteroarylaminer som glykogensyntase-kinase 3beta-inhibitorer (GSK3-inhibitorer)
AR030553A1 (es) Uso de derivados de tiazolilo 2,4-disustituidos para la fabricacion de un medicamento para la prevencion o el tratamiento de enfermedades mediadas a traves de citoquinas, derivados de tiazolilo 2,4-disustituidos, composiciones farmaceuticas que los comprenden, procesos para preparar dichos derivados
AR052559A1 (es) Derivados de pirazol para inhibir cdk's y gsk's
AR067327A1 (es) Derivados de piperidina / piperazina
NO2012010I2 (no) Rilpivirin samt farmasøytisk akseptable addisjonssalter derav innbefattende hydrokloridsaltet av Rilpivirin
WO2008007123A3 (en) Pharmaceutical compounds
ES2121223T3 (es) Derivados de indol como antagonistas de tromboxano a2.
TN2012000033A1 (en) Mixtures of mesoionic pesticides
RU2009148320A (ru) Производные пиперидина/пиперазина
GB0226724D0 (en) Therapeutic agents
EP1867331A4 (en) TRIAZOL DERIVATIVE AND ITS USE
BR0211887A (pt) Derivados de triazolil 2-amino-4,5-trissubstituìdo
CY1114767T1 (el) Ν,ν-υποκατεστημενες ενωσεις 3-αμινοπυρρολιδινης χρησιμες ως αναστολεις επαναπροσληψης μονοαμινων
AR066154A1 (es) Derivados de piperidina / piperazina
CY1110502T1 (el) Αντιμυκητικες 4-υποκατεστημενες 5,6-διϋδρο-4η-πυρρολο[1,2-α][1,4]βενζοδιαζεπινες
CO2020012353A2 (es) Compuestos de pirazol sustituidos con heteroarilo y uso farmacéutico de los mismos
AR066605A1 (es) Derivados de heteroarilamida pirimidona
WO2006075023A3 (en) Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
AR070073A1 (es) Derivados de imidazo[1, 2 - a]piridin-2-carboxamidas, intermediarios para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades que implican a los receptores not.
NO20065323L (no) 6-substituerte pyridoindolonderivater, fremstilling og anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application